Recruiting

PEP Reduction

Sponsor:

Methodist Health System

Code:

NCT07490132

Conditions

Gastro-Intestinal Disorder

Eligibility Criteria

Sex: All

Age: 15+

Healthy Volunteers: Not accepted

Interventions

Patients undergoing ERCPs at Methodist Dallas Medical Center

Study Details

Brief summary:

The risk of post-endoscopic retrograde cholangiopancreatography(ERCP) pancreatitis(PEP) is influenced by patient and procedure-related factors. Strategies to decrease PEP(Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis) are of great importance.

Conditions

Gastro-Intestinal Disorder

Study ID

NCT07490132

Start date

Feb, 2026

Status verified date

Feb, 2026

Completion date

Feb, 2028

Anticipated

Primary completion date

Feb, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 15+

Healthy Volunteers: Not accepted

Inclusion Criteria:

Patients >15 years Included in MDI's Registry Underwent ERCP between January 1, 2000 through December 31, 2025

Exclusion Criteria:

Patients <15 years Patients in which cannulation was via a surgical anastomosis Patients in which cannulation was not attempted due to gastric outlet obstruction, the main papilla not found, or the minor papilla was not found will be excluded.

Study Design

Enrollment

100 participants

Anticipated

Interventions and Outcome Measures

Arms

Underwent ERCP

Underwent ERCP between January 1, 2000 through December 31, 2025

Interventions

Patients undergoing ERCPs at Methodist Dallas Medical Center

The registry will include all patients who meet registry inclusion. Enrollment will terminate once 25 years of data are captured: January 1, 2000 through December 31, 2025.

Primary outcome measure

  • Underwent ERCP [ Time Frame: 25 years ]

Central Contacts and Locations

Central contacts

Crystee Cooper, DHEd

214-947-1280ClinicalResearch@mhd.com

Kavya Mankulangara

214-947-4604ClinicalResearch@mhd.com

Locations

Methodist Dallas Medical Center- Clinical Research Institute

Recruiting

Dallas, Texas, United States, 75203

Contacts

Colette Ngo Ndjom

214-947-1289ClinicalResearch@mhd.com

Kavya Mankulangara

214-947-4604ClinicalResearch@mhd.com

More Information

Sponsor

Methodist Health System

Last update posted

Mar 24, 2026

Last verified

Feb, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Methodist Health System on 2026-03-24.